Elpiscience
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An immuno-oncology company developing macrophage-targeting therapies to modulate the tumor microenvironment.
Oncology
Technology Platform
Integrated discovery platform focused on identifying and developing biologics that target and modulate myeloid cells in the tumor microenvironment.
Opportunities
Potential to develop breakthrough therapies for cancer patients resistant to current T-cell checkpoint inhibitors.
Risk Factors
Scientific risk associated with pioneering a novel immuno-oncology mechanism that is not yet clinically proven.
Competitive Landscape
An early mover in the competitive but promising field of myeloid-targeted immuno-oncology therapies.